Related Experiment Video

Updated: May 4, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

43.7K

RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses

Henok Eyob1, Huseyin Atakan Ekiz, Alana L Welm

  • 1Department of Oncological Sciences; Huntsman Cancer Institute; University of Utah; Salt Lake City, UT USA.

Oncoimmunology
|December 12, 2013
PubMed

Insights

The study reveals that inhibiting the MSP/RON pathway can boost anti-tumor immune responses. This approach may prevent micrometastatic lesions from growing into advanced cancer metastases.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • The Mesenchymal-Epithelial Transition (MET) signaling pathway, involving Macrophage Stimulating Protein (MSP) and its receptor RON, plays a crucial role in cancer progression.
  • This pathway is known to suppress anti-tumor immune responses, facilitating the transition of micrometastatic lesions to overt metastases.

Purpose of the Study:

  • To investigate the role of the MSP/RON signaling pathway in immune evasion during cancer metastasis.
  • To explore the potential of targeting RON to enhance anti-tumor immunity and inhibit metastatic outgrowth.

Main Methods:

  • The study likely involved preclinical models and immunological assays to assess the impact of RON signaling on T-cell responses.
  • Analysis of RON function in host cells and its effect on the tumor microenvironment.

Main Results:

  • Loss of RON function in the host was observed to potentiate tumor-specific CD8+ T-cell responses.
  • This potentiation of T-cell activity effectively inhibited the outgrowth of metastatic cancer cells.

Conclusions:

  • The MSP/RON signaling pathway actively suppresses anti-tumor immunity, promoting metastasis.
  • Inhibitors targeting RON present a promising therapeutic strategy for preventing the outgrowth of micrometastases in cancer patients.
Keywords:
CD8+ T-cell responseMSPRONTNFantitumor immunityimmunotherapymetastasistumor dormancytumor microenvironment

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

22.8K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K